ATL ULTRAMARK 9 WITH HDI: EXTENDED SIGNAL PROCESSING UPGRADE
This article was originally published in The Gray Sheet
Executive Summary
ATL ULTRAMARK 9 WITH HDI: EXTENDED SIGNAL PROCESSING UPGRADE deliveries will begin in June, Advanced Technology Laboratories, Inc. says in an April 19 release. The ESP upgrade to the Ultramark 9 with High Definition Imaging uses real-time parallel processing and system software to reduce "speckle noise," an artifact caused by "the random, artificial pattern of overlapping ultrasound echoes," according to ATL. The ESP option is being offered as part of a "level four" upgrade that also includes the C7-4 broadband curved array scanhead, the fifth addition to ATL's broadband scanhead line. The C7-4 provides "superior image quality" in obstetrical, superficial abdominal, and pediatric ultrasound examinations, ATL claims. The firm explains that the ESP parallel processing module and system software work together to "optimize the entire image formation path and extract further tissue information from the HDI broadband digital beamformer, without the compromises to image resolution required by conventional methodologies." The technology "more than doubles signal processing," and the resulting reduction of speckle noise "expands the potential of ultrasound to address diagnostic applications that were previously the domain of exploratory surgery and other more expensive or invasive imaging modalities," according to the firm. Benefits claimed for ESP include "enhanced visualization of subtle masses and tumors, clearer depiction of tissue changes associated with disease processes, more well-defined interfaces and tissue boundaries, greater confidence in the assessment of lesions and enhanced color Doppler for improved visualization of flow." The technology also provides "greater clarity of vessels and fluid-filled structures" and "improved characterization of arterial and venous disease states," ATL says. In addition, the "resolution of extremely fine detail" offered by the technology helps with imaging of small anatomical structures and early visualization of fetal development processes, according to the firm.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.